HOME > TOP STORIES

TOP STORIES

BUSINESS PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst

January 28, 2015
BUSINESS Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin

January 27, 2015
REGULATORY Japan-Version Compassionate Use May Cover Drugs with No Approval Globally

January 26, 2015
REGULATORY Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28

January 23, 2015
BUSINESS Open Tenders Good Example of Early Price Settlements: Qol Exec

January 22, 2015
ORGANIZATION Some LDP Members Keen to Tackle Kampo NHI Price Problem

January 21, 2015
REGULATORY R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017

January 21, 2015
REGULATORY R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways

January 20, 2015
REGULATORY PMDA Head Expresses Full Support for AMED

January 19, 2015
ORGANIZATION JPMA Notifies of Unfavorable Expressions for Disease Awareness Ads

January 16, 2015
ORGANIZATION Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading

January 15, 2015
INTERVIEW EFPIA Japan Chairman Says Drug Costs Won’t Explode

January 14, 2015
ORGANIZATION Wholesalers Must Revamp Biz Model to Cope with Change in Sales Mix: JPWA Chief

January 14, 2015
REGULATORY MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors

January 13, 2015
ORGANIZATION Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President

January 9, 2015
REGULATORY 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division

January 8, 2015
REGULATORY Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau

January 7, 2015
REGULATORY Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions

January 6, 2015
ORGANIZATION FPMAJ Chairman Wishes for Good Environment for Drug Innovation in 2015

January 1, 2015
TRENDS ARBs at a Turning Point: Inroads by Generics to Lead to Gradual Decline in Sales

December 26, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…